Assenagon Asset Management S.A. Buys 5,565 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Assenagon Asset Management S.A. increased its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 0.5% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,146,812 shares of the company's stock after purchasing an additional 5,565 shares during the period. Assenagon Asset Management S.A. owned 3.00% of Tarsus Pharmaceuticals worth $63,499,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Jennison Associates LLC grew its position in shares of Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company's stock valued at $71,653,000 after purchasing an additional 698,712 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock valued at $14,477,000 after buying an additional 420,057 shares during the period. Millennium Management LLC grew its position in Tarsus Pharmaceuticals by 1,259.3% during the second quarter. Millennium Management LLC now owns 348,586 shares of the company's stock worth $9,475,000 after buying an additional 322,942 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in Tarsus Pharmaceuticals during the third quarter worth about $10,587,000. Finally, Vestal Point Capital LP bought a new position in Tarsus Pharmaceuticals in the 3rd quarter worth about $7,565,000. Institutional investors own 90.01% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TARS. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $54.20.

Tarsus Pharmaceuticals Price Performance

NASDAQ:TARS traded up $0.36 during mid-day trading on Thursday, reaching $46.92. The stock had a trading volume of 437,805 shares, compared to its average volume of 953,750. The stock has a market capitalization of $1.79 billion, a P/E ratio of -12.31 and a beta of 1.02. The firm has a 50 day moving average price of $51.01 and a two-hundred day moving average price of $38.08. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.14.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.